Structural basis of HIV-1 neutralization by affinity matured fabs directed against the internal trimeric coiled-coil of gp41

PLoS Pathogens

Volumn 6, Issue 11, 2010, Pages

  Gustchina, Elena ^a   Li, Mi ^b,c   Louis, John M ^a   Eric Anderson, D ^a   Lloyd, John ^a   Frisch, Christian ^d   Bewley, Carole A ^a   Gustchina, Alla ^b   Wlodawer, Alexander ^b   Marius Clore, G ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d MORPHOSYS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 41; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY LIBRARY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; CRYSTAL STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; VIRUS NEUTRALIZATION; VIRUS STRAIN; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; SERODIAGNOSIS; X RAY CRYSTALLOGRAPHY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CRYSTALLOGRAPHY, X-RAY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 79251527490     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1001182     Document Type: Article

References (52)

1. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700.
2. Eckert DM, Kim PS (2001a) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777-810.
3. Furuta RA, Wild CT, Weng Y, Weiss CD (1998) Capture of an early fusionactive conformation of HIV-1 gp41. Nature Struct Biol 5: 276-279.
4. Chan DC, Kim PS (1998) HIV entry and its inhibition. Cell 93: 681-684.
5. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, et al. (2000) Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151: 413-423.
6. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, et al. (2003) The HIV Env-mediated fusion reaction. Biochim Biophys Acta 1614: 36-50.
7. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
8. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
9. Tan K, Liu J, Wang J, Shen S, Lu M (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 94: 12303-12308.
10. Caffrey M, Cai M, Kaufman J, Stahl SJ, Wingfield PT, et al. (1998) Threedimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J 17: 4572-4584.
11. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 89: 10537-10541.
12. Jiang S, Lin K, Strick N, Neurath AR (1993) HIV-1 inhibition by a peptide. Nature 365: 113.
13. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91: 9770-9774.
14. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS (1999) Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99: 103-115.
15. Root MJ, Kay MS, Kim PS (2001) Protein design of an HIV-1 entry inhibitor. Science 291: 884-888.
16. Louis JM, Bewley CA, Clore GM (2001) Design and properties of NCCG-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem 276: 29485-29489.
17. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41. J Virol 75: 10892-10905.
18. Eckert DM, Kim PS (2001b) Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci U S A 98: 11187-11192.
19. Bewley CA, Louis JM, Ghirlando R, Clore GM (2002) Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem 277: 14238-14245.
20. Golding H, Zaitseva M, de Rosny E, King LR, Manischewitz J, et al. (2002) Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 76: 6780-6790.
21. Louis JM, Nesheiwat I, Chang L, Clore GM, Bewley CA (2003) Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 278: 20278-20285.
22. Root MJ, Steger HK (2004) HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 10: 1805-1825.
23. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, et al. (2004) Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nature Rev Drug Discov 3: 215-225.
24. Louis JM, Bewley CA, Gustchina E, Aniana A, Clore GM (2005) Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41. J Mol Biol 353: 945-951.
25. Gustchina E, Hummer G, Bewley CA, Clore GM (2005) Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. J Med Chem 48: 3036-3044.
26. Gustchina E, Louis JM, Bewley CA, Clore GM (2006) Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41. J Mol Biol 364: 283-289.
27. Steger HK, Root MJ (2006) Kinetic dependence to HIV-1 entry inhibition. J Biol Chem 281: 25813-25821.
28. Eckert DM, Shi Y, Kim S, Welch BD, Kang E, et al. (2008) Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci 17: 2091-2100.
29. Gustchina E, Bewley CA, Clore GM (2008) Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41. J Virol 82: 10032-10041.
30. Hrin R, Montgomery DL, Wang F, Condra JH, An Z, et al. (2008) Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. AIDS Res Hum Retroviruses 24: 1537-1544.
31. Kahle KM, Steger HK, Root MJ (2009) Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog 5: e1000674.
32. Bianchi E, Joyce JG, Miller MD, Finnefrock AC, Liang X, et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A 107: 10655-10660.
33. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5: e8805.
34. Miller MD, Geleziunas R, Bianchi E, Lennard S, Hrin R, et al. (2005) A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 102: 14759-14764.
35. Gustchina E, Louis JM, Lam SN, Bewley CA, Clore GM (2007) A Monoclonal Fab Derived From a Human Non-Immune Phage Library Reveals a New Epitope on gp41 and Neutralizes Diverse HIV-1 Strains. J Virol 81: 12946-12953.
36. Choudhry V, Zhang MY, Sidorov IA, Louis JM, Harris I, et al. (2007) Crossreactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363: 79-90.
37. Zhang MY, Vu BK, Choudhary A, Lu H, Humbert M, et al. (2008) Crossreactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. J Virol 82: 6869-6879.
38. Nelson JD, Kinkead H, Brunel FM, Leaman D, Jensen R, et al. (2008) Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV- 1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377: 170-183.
39. Gustchina E, Louis JM, Frisch C, Ylera F, Lechner A, et al. (2009) Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naive human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth. Virology 393: 112-119.
40. Montgomery DL, Wang YJ, Hrin R, Luftig M, Su B, et al. (2009) Affinity maturation and characterization of a human monoclonal antibody against HIV- 1 gp41. MAbs 1: 462-474.
41. Luftig MA, Mattu M, Di Giovine P, Geleziunas R, Hrin R, et al. (2006) Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nature Struct Mol Biol 13: 740-747.
42. Rothe C, Urlinger S, Lohning C, Prassler J, Stark Y, et al. (2008) The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 376: 1182-1200.
43. Reynolds C, Damerell D, Jones S (2009) ProtorP: a protein-protein interaction analysis server. Bioinformatics 25: 413-414.
44. Kuiken C, Foley B, Marx P, Wolinsky S, Leitner T, et al. (2009) HIV Sequence Compendium 2009. Los Alamos: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory. pp 352-359.
45. Hunt DF, Yates JR, 3rd, Shabanowitz J, Winston S, Hauer CR (1986) Protein sequencing by tandem mass spectrometry. Proc Natl Acad Sci U S A 83: 6233-6237.
46. Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850-858.
47. Yu YQ, Gilar M, Lee PJ, Bouvier ES, Gebler JC (2003) Enzyme-friendly, mass spectrometry-compatible surfactant for in-solution enzymatic digestion of proteins. Anal Chem 75: 6023-6028.
48. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
49. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255.
50. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
51. Chothia C, Lesk AM (1987) Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196: 901-917.
52. Kuszewski J, Gronenborn AM, Clore GM (1999) Improving the packing and accuracy of NMR structures with a pseudopotential for the radius of gyration. J Am Chem soc 121: 2337-2338.